Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. | Ann Oncol;20(5): 967, 2009 May. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Search Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search

Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

Bono, P; Joensuu, H.

Affiliation

Bono P; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. Electronic address: petri.bono@hus.fi.
Joensuu H; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

Ann Oncol ; 20(5): 967, 2009 May.

Article in En | MEDLINE | ID: mdl-32560016

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2009 Type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2009 Type: Article